Mirko Ancillotti

Mirko Ancillotti

Mirko Ancillotti

PhD, Researcher

Mirko Ancillotti is a post-doc researcher at CRB. His research areas are public health and applied ethics and his interests include health preference research. His background is in philosophy, which he studied at the University of Valencia, Spain, and at the University of Pisa, Italy, where he earned a master of arts in 2012. His master thesis covered John Harris’ influence on contemporary bioethical debate on cloning and enhancement. In 2021, he earned his PhD in medical sciences from Uppsala University, and the Centre for Research Ethics & Bioethics, where he started working in September 2013. From 2014 to 2015, he worked on a research project on public understanding and media portrayal of synthetic biology before starting his PhD project on antibiotic resistance and the role of individual responsibility and behaviour.

He is currently involved in the EU projects ENLIGHTENme and OncoLogics. ENLIGHTENme studies how urban lighting affects the population's health and well-being. Together with Deborah Mascalzoni, Mirko Ancillotti works on the ethical aspects of the project, considering also the effects of light pollution on other life forms. OncoLogics aims at creating a platform for personalised colorectal cancer clinical therapy decision support. Together with CRB colleagues Deborah Mascalzoni, Åsa Grauman, and Jorien Veldwijk, Mirko Ancillotti studies the medical ethics aspects of the project and works on the elucidation and integration of patients’ preferences in the development of the decision support platform.

Follow Mirko Ancillotti on TwitterResearchGate and Academia, or visit his website

E-mail: mirko.ancillotti@crb.uu.se

Publications

Synthetic biology, ethics and antibiotics

Who shapes public opinion of science? How do people make trade-offs between risks and benefits of technology that could both help and harm? Mirko Ancillotti is moving from media portrayal of synthetic biology to antibiotic resistance and the ethical aspects of using a new kind of peptide-based antibiotics.

Read interview

Mirko Ancillotti
Last modified: 2022-02-01